Programa de Pós-Graduação em Saúde da Criança e do Adolescente, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil.
Programa de Pós-Graduação em Patologia, Universidade Federal de Ciências da Saúde de Porto Alegre - Porto Alegre (RS), Brasil.
Rev Bras Ter Intensiva. 2022 Oct-Dec;34(4):507-518. doi: 10.5935/0103-507X.20220145-pt. Epub 2023 Mar 3.
To verify strategies for the prevention and treatment of abstinence syndrome in a pediatric intensive care unit.
This is a systematic review in the PubMed database®, Lilacs, Embase, Web of Science, Cochrane, Cinahl, Cochrane Database Systematic Review and CENTRAL. A three-step search strategy was used for this review, and the protocol was approved in PROSPERO (CRD42021274670).
Twelve articles were included in the analysis. There was great heterogeneity among the studies included, especially regarding the therapeutic regimens used for sedation and analgesia. Midazolam doses ranged from 0.05mg/kg/hour to 0.3mg/kg/hour. Morphine also varied considerably, from 10mcg/kg/hour to 30mcg/kg/hour, between studies. Among the 12 selected studies, the most commonly used scale for the identification of withdrawal symptoms was the Sophia Observational Withdrawal Symptoms Scale. In three studies, there was a statistically significant difference in the prevention and management of the withdrawal syndrome due to the implementation of different protocols (p < 0.01 and p < 0.001).
There was great variation in the sedoanalgesia regimen used by the studies and the method of weaning and evaluation of withdrawal syndrome. More studies are needed to provide more robust evidence about the most appropriate treatment for the prevention and reduction of withdrawal signs and symptoms in critically ill children.
CRD 42021274670.
验证小儿重症监护病房戒断综合征的预防和治疗策略。
这是在 PubMed 数据库®、Lilacs、Embase、Web of Science、Cochrane、Cinahl、Cochrane 系统评价数据库和 CENTRAL 中进行的系统评价。该综述采用了三步搜索策略,方案已在 PROSPERO(CRD42021274670)中获得批准。
共有 12 篇文章纳入分析。纳入的研究之间存在很大的异质性,特别是在镇静和镇痛的治疗方案方面。咪达唑仑的剂量范围为 0.05mg/kg/h 至 0.3mg/kg/h。吗啡的剂量也有很大差异,从 10mcg/kg/h 到 30mcg/kg/h。在 12 项选定的研究中,最常用于识别戒断症状的量表是 Sophia 观察性戒断症状量表。在 3 项研究中,由于实施了不同的方案,戒断综合征的预防和管理存在统计学上的显著差异(p<0.01 和 p<0.001)。
研究中镇静镇痛方案的使用以及戒断和评估戒断综合征的方法存在很大差异。需要更多的研究提供更有力的证据,以确定最适合治疗危重症儿童戒断症状和体征的方法。
PROSPERO 注册号:CRD42021274670。